CSF3 and neutropenia: Recent prospective data from the PRIMED trial (44) demonstrated that primary prophylactic administration of G-CSF and loperamide significantly reduced the incidence and severity of SG-related neutropenia and numerically lowered SG-related diarrhea, thereby decreasing rates of dose reductions (14%) and temporary treatment interruptions (30%), with no treatment discontinuations during the first two cycles.